Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which of it primarily is targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, the Company is primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100 milligrams (mg) of resveratrol. It has a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
BörsenkürzelJUNS
Name des UnternehmensJupiter Neurosciences Inc
IPO-datumDec 03, 2024
Gegründet am2016
CEOMr. Christer Rosen
Anzahl der mitarbeiter4
WertpapierartOrdinary Share
GeschäftsjahresendeDec 03
Addresse1001 North US HWY 1, Suite 504
StadtPALM BEACH GARDENS
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl33477
Telefon15614066154
Websitehttps://jupiterneurosciences.com/
BörsenkürzelJUNS
IPO-datumDec 03, 2024
Gegründet am2016
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten